Skip to main content
main-content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

Health and Quality of Life Outcomes 1/2012

Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey

Zeitschrift:
Health and Quality of Life Outcomes > Ausgabe 1/2012
Autoren:
Iftekhar Kalsekar, Jan-Samuel Wagner, Marco DiBonaventura, Jay Bates, Robert Forbes, Tony Hebden
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7525-10-81) contains supplementary material, which is available to authorized users.

Competing interests

This study was conducted by Kantar Health on behalf of Bristol-Myers Squibb, which funded the study. MD is a full-time employee of Kantar Health. JSW was a full-time employee of Kantar Health at the time of this study and is now a student at Columbia University. IK, JB, and TH are full-time employees at Bristol-Myers Squibb. RF is a full-time employee at Otsuka Pharmaceuitcal Development & Commercialization.

Authors’ contributions

IK participated in the conception, design, coordination, and analysis of the study. JSW was involved in the coordination and analysis of the study and drafted the manuscript. MD was engaged in the conception and design of the study and participated in the manuscript’s drafting and editing. JB, RF, and TH provided content expertise and editorial insight. All authors read and approved the final manuscript.

Abstract

Background

Use of atypical antipsychotics (AA) in combination with an antidepressant is recommended as an augmentation strategy for patients with depression. However, there is a paucity of data comparing aripiprazole and other AAs in terms of patient reported outcomes. Therefore, the objective of this study was to examine the levels of HRQoL and health utility scores in patients with depression using aripiprazole compared with patients using olanzapine, quetiapine, risperidone and ziprasidone.

Methods

Data were obtained from the 2009, 2010, and 2011 National Health and Wellness Survey (NHWS), a cross-sectional, internet-based survey that is representative of the adult US population. Only those patients who reported being diagnosed with depression and taking an antidepressant and an atypical antipsychotic for depression were included. Patients taking an atypical antipsychotic for less than 2 months or who reported being diagnosed with bipolar disorder or schizophrenia were excluded. Patients taking aripiprazole were compared with patients taking other atypical antipsychotics. Health-related quality of life (HRQoL) and health utilities were assessed using the Short Form 12-item (SF-12) health survey. Differences between groups were analyzed using General Linear Models (GLM) controlling for demographic and health characteristics.

Results

Overall sample size was 426 with 59.9% taking aripiprazole (n = 255) and 40.1% (n = 171) taking another atypical antipsychotic (olanzapine (n = 19), quetiapine (n = 127), risperidone (n = 14) or ziprasidone (n = 11)). Of the SF-12 domains, mean mental component summary (MCS) score (p = .018), bodily pain (p = .047), general health (p = .009) and emotional role limitations (p = .009) were found to be significantly higher in aripiprazole users indicating better HRQoL compared to other atypical antipsychotics. After controlling for demographic and health characteristics, patients taking aripiprazole reported significantly higher mean mental SF-12 component summary (34.10 vs. 31.43, p = .018), bodily pain (55.19 vs. 49.05, p = .047), general health (50.05 vs. 43.07, p = .009), emotional role limitations (49.44 vs. 41.83, p = .009), and SF-6D utility scores (0.59 vs. 0.56, p = .042).

Conclusions

Comparison of patients taking aripiprazole with a cohort of patients using another AA for depression demonstrated that aripiprazole was independently associated with better (both statistically and clinically) HRQoL and health utilities.
Zusatzmaterial
Additional file 1: List of medications included in the definition of antidepressant treatment. (PDF 52 KB)
12955_2012_939_MOESM1_ESM.pdf
Authors’ original file for figure 1
12955_2012_939_MOESM2_ESM.pdf
Authors’ original file for figure 2
12955_2012_939_MOESM3_ESM.pdf
Authors’ original file for figure 3
12955_2012_939_MOESM4_ESM.pdf
Authors’ original file for figure 4
12955_2012_939_MOESM5_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Health and Quality of Life Outcomes 1/2012 Zur Ausgabe